scholarly journals Large Cell Neuroendocrine Carcinoma of the Rectum Presenting with Extensive Metastatic Disease

2014 ◽  
Vol 2014 ◽  
pp. 1-5 ◽  
Author(s):  
Vinay Minocha ◽  
Sania Shuja ◽  
Robert Ali ◽  
Emely Eid
Keyword(s):  
Neuroendocrine Carcinoma ◽  
Metastatic Disease ◽  
Lower Abdominal Pain ◽  
Large Cell ◽  
Large Cell Neuroendocrine Carcinoma ◽  
Pathological Examination ◽  
Resected Specimen ◽  
Rectal Mass ◽  
Poorly Differentiated ◽  
Neuroendocrine Carcinomas

Introduction. Rectal large cell neuroendocrine carcinoma (LCNEC) is a poorly differentiated neoplasm that is very rare and belongs within the poorest prognostic subgroup among primary colorectal neoplasms. Here, we describe a case of LCNEC of the rectum, which highlights the aggressive clinical course and poor prognosis associated with this disease.Case Presentation. We report a case of a 63-year-old male who presented to our hospital with a one-month history of lower abdominal pain, constipation, and weight loss. A computed tomography (CT) scan of the chest, abdomen, and pelvis revealed a rectal mass as well as metastatic disease of the liver and lung. Flexible sigmoidoscopy revealed a fungating, ulcerated and partially obstructing rectal mass located 6 cm from the anal verge. This mass was biopsied and pathological examination of the resected specimen revealed features consistent with a large cell neuroendocrine carcinoma.Conclusion. Rectal large cell neuroendocrine carcinomas are rare and have a significantly worse prognosis than adenocarcinomas. At diagnosis, a higher stage and metastatic disease are likely to be found. It is important to differentiate large cell, poorly differentiated neuroendocrine carcinomas from adenocarcinomas of the colon and rectum pathologically because patients may benefit from alternative cytotoxic chemotherapeutic regimens.

scholarly journals Large-Cell Neuroendocrine Carcinoma of the Esophagus: A Case from Saudi Arabia

2015 ◽  
Vol 9 (3) ◽  
pp. 327-334 ◽  
Author(s):  
Hadi Kuriry ◽  
Abdul Monem Swied
Keyword(s):  
Weight Loss ◽  
Neuroendocrine Carcinoma ◽  
Large Cell ◽  
Large Cell Neuroendocrine Carcinoma ◽  
High Grade ◽  
Upper Endoscopy ◽  
Carcinoma Of The Esophagus ◽  
Poorly Differentiated ◽  
Neuroendocrine Carcinomas ◽  
Progressive Dysphagia

Neuroendocrine carcinomas of the esophagus are very rare, and the majority are high grade (poorly differentiated). They occur most frequently in males in their sixth and seventh decades of life. There have been no concrete data published on clinical features or on prognosis. We report a case of large-cell neuroendocrine carcinoma of the esophagus in a 66-year-old Saudi female with progressive dysphagia and weight loss. Upper endoscopy revealed an esophageal ulcerated mass.

Pulmonary Neuroendocrine Carcinomas

2002 ◽  
Vol 126 (5) ◽  
pp. 545-553 ◽  
Author(s):  
Qin Huang ◽  
Alona Muzitansky ◽  
Eugene J. Mark
Keyword(s):  
Neuroendocrine Tumors ◽  
Neuroendocrine Carcinoma ◽  
Large Cell ◽  
Small Cell ◽  
The Body ◽  
Low Grade ◽  
Typical Carcinoid ◽  
Poorly Differentiated Neuroendocrine Carcinoma ◽  
Poorly Differentiated ◽  
Neuroendocrine Carcinomas

Abstract Context.—Primary pulmonary neuroendocrine tumors are traditionally classified into 3 major types: typical carcinoid (TC), atypical carcinoid (AC), and large cell neuroendocrine carcinoma (LC) or small cell neuroendocrine carcinoma (SC). Confusion arises frequently regarding the malignant nature of TC and the morphologic differentiation between AC and LC or SC. Objective.—To provide clinicopathologic evidence to streamline and clarify the histomorphologic criteria for this group of tumors, emphasizing the prognostic implications. Patients.—To minimize variability in diagnostic criteria and treatment plans, we analyzed a group of patients whose diagnosis and treatment occurred at a single institution. We reviewed 234 cases of primary pulmonary neuroendocrine tumors and thoroughly studied 50 cases of resected tumors from 1986 to 1995. Results.—On the basis of morphologic characteristics and biologic behaviors of the tumors, we agree with many previous investigators that these tumors are all malignant and potentially aggressive. Based on our accumulated data, we have modified Gould criteria and reclassified these tumors into 5 types: (1) well-differentiated neuroendocrine carcinoma (otherwise called TC) (14 cases, with less than 1 mitosis per 10 high-power fields [HPF] with or without minimal necrosis); (2) moderately differentiated neuroendocrine carcinoma (otherwise called low-grade AC) (6 cases, with less than 10 mitoses per 10 HPF and necrosis evident at high magnification); (3) poorly differentiated neuroendocrine carcinoma (otherwise called high-grade AC) (10 cases, with more than 10 mitoses per 10 HPF and necrosis evident at low-power magnification); (4) undifferentiated LC (5 cases, with more than 30 mitoses per 10 HPF and marked necrosis); and (5) undifferentiated SC (15 cases, with more than 30 mitoses per 10 HPF and marked necrosis). The 5-year survival rates were 93%, 83%, 70%, 60%, and 40% for well, moderately, and poorly differentiated, and undifferentiated large cell and small cell neuroendocrine carcinomas, respectively. We found nodal metastasis in 28% of TC in this retrospective review, a figure higher than previously recorded. Conclusion.—Using a grading system and terms comparable to those used for many years and used for neuroendocrine tumors elsewhere in the body, we found that classification of pulmonary neuroendocrine carcinomas as well, moderately, poorly differentiated, or undifferentiated provides prognostic information and avoids misleading terms and concepts. This facilitates communication between pathologists and clinicians and thereby improves diagnosis and management of the patient.

scholarly journals Poorly Differentiated Large Cell Neuroendocrine Carcinoma of the Colon: A Case Report

Cureus ◽  
2022 ◽  
Author(s):  
Kelsee Felux ◽  
Burke McCarty ◽  
Dennis Turner ◽  
TKeyah Gray ◽  
Vijaykumar Patel
Keyword(s):  
Case Report ◽  
Neuroendocrine Carcinoma ◽  
Large Cell ◽  
Large Cell Neuroendocrine Carcinoma ◽  
Carcinoma Of The Colon ◽  
Poorly Differentiated

scholarly journals Molecular Pathology of Pulmonary Large Cell Neuroendocrine Carcinoma: Novel Concepts and Treatments

2021 ◽  
Vol 11 ◽  
Author(s):  
Masayo Yoshimura ◽  
Kurumi Seki ◽  
Andrey Bychkov ◽  
Junya Fukuoka
Keyword(s):  
Neuroendocrine Carcinoma ◽  
Molecular Subtypes ◽  
Small Cell Lung Carcinoma ◽  
Large Cell ◽  
Large Cell Neuroendocrine Carcinoma ◽  
Type I ◽  
Histologic Diagnosis ◽  
Cell Lung Carcinoma ◽  
Genomic Studies ◽  
Poorly Differentiated

Pulmonary large cell neuroendocrine carcinoma (LCNEC) is an aggressive neoplasm with poor prognosis. Histologic diagnosis of LCNEC is not always straightforward. In particular, it is challenging to distinguish small cell lung carcinoma (SCLC) or poorly differentiated carcinoma from LCNEC. However, histological classification for LCNEC as well as their therapeutic management has not changed much for decades. Recently, genomic and transcriptomic analyses have revealed different molecular subtypes raising hopes for more personalized treatment. Two main molecular subtypes of LCNEC have been identified by studies using next generation sequencing, namely type I with TP53 and STK11/KEAP1 alterations, alternatively called as non-SCLC type, and type II with TP53 and RB1 alterations, alternatively called as SCLC type. However, there is still no easy way to classify LCNEC subtypes at the actual clinical level. In this review, we have discussed histological diagnosis along with the genomic studies and molecular-based treatment for LCNEC.

scholarly journals Poorly differentiated large cell neuroendocrine carcinoma of the gallblader

2017 ◽  
Vol 6 (5) ◽  
pp. 3913-3915
Author(s):  
Sinaa Mohamed ◽  
◽  
Oukabli Mohamed ◽  
Albouzidi Abderrahmane ◽  
◽  
...  
Keyword(s):  
Neuroendocrine Carcinoma ◽  
Large Cell ◽  
Large Cell Neuroendocrine Carcinoma ◽  
Poorly Differentiated

scholarly journals Primary MiNEN of the urinary bladder: an hitherto undescribed entity composed of large cell neuroendocrine carcinoma and adenocarcinoma with a distinct clinical behavior

2021 ◽  
Author(s):  
Giacomo Maria Pini ◽  
Silvia Uccella ◽  
Matteo Corinti ◽  
Maurizio Colecchia ◽  
Giuseppe Pelosi ◽  
...  
Keyword(s):  
Urinary Bladder ◽  
Urothelial Carcinoma ◽  
Neuroendocrine Carcinoma ◽  
Metastatic Disease ◽  
Large Cell ◽  
Small Cell ◽  
Neuroendocrine Neoplasms ◽  
Unique Case ◽  
Clinical Behavior ◽  
Neuroendocrine Carcinomas

AbstractNeuroendocrine carcinomas (NECs) of the urinary bladder are very rare and can be observed in the context of mixed neuroendocrine/non-neuroendocrine neoplasms (MiNENs), most frequently in association with urothelial carcinoma. Small cell NECs are far more common than large cell NECs (LCNECs), which are exceedingly rare. We describe a primary MiNEN of the urinary bladder, composed of a LCNEC and of an adenocarcinoma, in which the neuroendocrine component reached complete pathological regression after neoadjuvant M-VAC chemotherapy, whereas the non-neuroendocrine component of the tumor progressed to metastatic disease. Compared to mixed neuroendocrine/non-neuroendocrine neoplasms described in the literature until now, this appears to be a unique case that expands the spectrum of neuroendocrine neoplasia of the urinary bladder.

Primary Large Cell Neuroendocrine Carcinoma of the Urinary Bladder

2002 ◽  
Vol 126 (10) ◽  
pp. 1229-1232 ◽  
Author(s):  
Andrew J. Evans ◽  
Jaudah Al-Maghrabi ◽  
John Tsihlias ◽  
Ginette Lajoie ◽  
Joan M. Sweet ◽  
...  
Keyword(s):  
Urinary Bladder ◽  
Neuroendocrine Carcinoma ◽  
Metastatic Disease ◽  
Transurethral Resection ◽  
Preoperative Staging ◽  
Muscularis Propria ◽  
Large Cell ◽  
Large Cell Neuroendocrine Carcinoma ◽  
Rapid Progression ◽  
Solitary Lesion

Abstract Reports of primary large cell neuroendocrine carcinomas of the urinary bladder are few; we identified only 2 cases in the literature. Both of these cases involved male patients with rapid progression of disease culminating in death with widespread metastases. We report a case of primary large cell neuroendocrine carcinoma of the bladder, with an admixed minor element of adenocarcinoma, in an 82-year-old man. This solitary lesion arose in a bladder diverticulum lateral to the left ureteric orifice. Two attempts at transurethral resection were unsuccessful at achieving local control. The patient underwent a partial cystectomy with left-sided pelvic lymphadenectomy following preoperative staging investigations that found no metastatic disease. Pathologically, the tumor invaded into the deep aspect of the muscularis propria, without extension into perivesical fat. The lateral resection margin was microscopically positive for tumor, but no malignancy was found in the pelvic lymph nodes. The adenocarcinoma comprised less than 5% of total tumor volume, and areas of transition between the neuroendocrine and adenocarcinoma components were apparent. The patient developed a local recurrence 8 months postoperatively, which was managed by a combination of transurethral resection and radiation therapy. Currently, the patient has no evidence of local or metastatic disease 2 years after initial diagnosis.

scholarly journals Poorly differentiated large-cell neuroendocrine carcinoma of the paranasal sinus

2018 ◽  
Vol 51 (4) ◽  
pp. 269-269 ◽  
Author(s):  
Helder Groenwold Campos ◽  
Albina Messias Altemani ◽  
João Altemani ◽  
Davi Ferreira Soares ◽  
Fabiano Reis
Keyword(s):  
Paranasal Sinus ◽  
Neuroendocrine Carcinoma ◽  
Large Cell ◽  
Large Cell Neuroendocrine Carcinoma ◽  
Poorly Differentiated
Sign in / Sign up

Export Citation Format

Share Document